Dennis Benjamin
Overview
Explore the profile of Dennis Benjamin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ryan M, Corinna Palanca-Wessels M, Schimpf B, Gordon K, Kostner H, Meyer B, et al.
Blood
. 2017 Sep;
130(18):2018-2026.
PMID: 28903943
Patients with relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma (B-NHL) or acute lymphoblastic leukemia have a poor prognosis. Despite measurable clinical activity with new targeted therapies, many patients do not...
2.
Mattie M, Raitano A, Morrison K, Morrison K, An Z, Capo L, et al.
Mol Cancer Ther
. 2016 Aug;
15(11):2679-2687.
PMID: 27550944
Here, we report the development of an antibody-drug conjugate, ASG-5ME, which targets the solute carrier receptor SLC44A4. SLC44A4 is a member of a family of putative choline transporters that we...
3.
Arico-Muendel C, Belanger B, Benjamin D, Blanchette H, Caiazzo T, Centrella P, et al.
Drug Metab Dispos
. 2013 Jan;
41(4):814-26.
PMID: 23355637
The natural product fumagillin exhibits potent antiproliferative and antiangiogenic properties. The semisynthetic analog PPI-2458, [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-[(2R)-1-amino-3-methyl-1-oxobutan-2-yl]carbamate, demonstrates rapid inactivation of its molecular target, methionine aminopeptidase-2 (MetAP2), and good efficacy in...
4.
Lacy S, Bond C, Benjamin D, Gerber H, Dimitrov D, Reichert J
MAbs
. 2010 Jan;
1(6):523-30.
PMID: 20068395
The Americas Antibody Congress, organized by Terrapinn, was held in Washington, D.C. on September 21-23, 2009. The conference sessions were expertly moderated by Herren Wu (MedImmune), and featured 26 speakers...
5.
Gerber H, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, et al.
Blood
. 2009 Jan;
113(18):4352-61.
PMID: 19147785
Despite major advances in the treatment of non-Hodgkin lymphoma (NHL), including the use of chemotherapeutic agents and the anti-CD20 antibody rituximab, the majority of patients eventually relapse, and salvage treatments...